Lead optimization of antimalarial propafenone analogues

David Lowes, Anupam Pradhan, Lalitha V. Iyer, Toufan Parman, Jason Gow, Fangyi Zhu, Anna Furimsky, Andrew Lemoff, W. Armand Guiguemde, Martina Sigal, Julie A. Clark, Emily Wilson, Liang Tang, Michele C. Connelly, Joseph L. Derisi, Dennis E. Kyle, Jon Mirsalis, R. Kiplin Guy

Research output: Contribution to journalArticle

9 Scopus citations


Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria. Careful examination of the bioavailability, pharmacokinetics, toxicology, and efficacy of this series of compounds using rodent models revealed orally bioavailable compounds that are nontoxic and suppress parasitemia in vivo. Although these compounds possess potential for further preclinical development, they also carry some significant challenges.

Original languageEnglish (US)
Pages (from-to)6087-6093
Number of pages7
JournalJournal of Medicinal Chemistry
Issue number13
StatePublished - Jul 12 2012


ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Lowes, D., Pradhan, A., Iyer, L. V., Parman, T., Gow, J., Zhu, F., Furimsky, A., Lemoff, A., Guiguemde, W. A., Sigal, M., Clark, J. A., Wilson, E., Tang, L., Connelly, M. C., Derisi, J. L., Kyle, D. E., Mirsalis, J., & Guy, R. K. (2012). Lead optimization of antimalarial propafenone analogues. Journal of Medicinal Chemistry, 55(13), 6087-6093. https://doi.org/10.1021/jm300286a